TCT 2021 | FAVOR III: Angiography-Derived FFR: An Event-Prevention Tool

Compared with visual estimation of lesions, using quantitative angiography-derived fractional flow reserve (quantitative flow ration, QFR) provides better clinical outcomes at one year for angioplasty. These results emerge from the Chinese FAVOR III study, presented at the 2021 TCT scientific sessions and simultaneously published in The Lancet.

TCT 2021 | FAVOR III: FFR derivado de la angiografía: Una herramienta que ahorra eventos

The simplicity and safety offered by QRF—since there is no lesion crossover with a guidewire—should facilitate its implementation in daily clinical practice.

Despite the evidence and the recommendations in all guidelines, fractional flow reserve (FFR) is underused worldwide. This is probably due to several factors: longer procedure time, complications with the guidewire, adverse effects of adenosine (not for iFR), and—last, but not least—costs.

FAVOR III included 3847 patients with stable or unstable coronary disease in 26 sites in China. The primary endpoint was a composite of all-cause mortality, infarction, or ischemia-driven revascularization at 1 year of follow-up.

This composite was significantly lower in those who underwent QFR compared with conventional angiography (5.8% vs. 8.8%; p = 0.0004).

This difference was mostly driven by a lower incidence of infarction in the QRF arm (44 less).


Read also: TCT 2021 | SUGAR Trial: Polymer-Free Stent in Diabetes.


A limitation for this study is that the control group was only assessed using angiography. It would have been interesting to use FFR and compare QFR vs. FFR head-to-head. Additionally, about 20% of patients were not good candidates for QFR due to juxtaposition of other vessels or low imaging quality.

QFR still has a long way to go, but it seems to be arriving at the right time. FFR has had negative outcomes in FAME 3, in stable patients, and in FLOWER-AMI, in acute patients.

Original Title: Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomized, sham-controlled trial.

Reference: Xu B et al. Lancet. 2021; Epub ahead of print y presentado simultáneamente en TCT 2021.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...